Lunesta (Eszopiclone) in Children Under 12: What to Know About Transitioning to Adult Care

Why Eszopiclone Is Not Approved for Children Under 12

Eszopiclone has never received FDA approval for pediatric patients of any age. The FDA-approved label covers adults with insomnia only, and a 2014 label revision lowered the recommended starting dose to 1 mg for all adults after post-marketing data linked the original 2 mg starting dose to next-morning impaired driving, particularly in women. [1]

The mechanism explains some of the developmental concern. Eszopiclone binds non-selectively to GABA-A receptor subunits, including alpha-1, alpha-2, alpha-3, and alpha-5 subtypes. [2] In developing brains, GABAergic signaling plays an organizing role in cortical maturation, and disrupting it pharmacologically carries theoretical risks that do not apply equally to adult CNS architecture.

The Terminated Pediatric Trial

The clearest clinical signal comes from an industry-sponsored randomized controlled trial examining eszopiclone 1 mg or 2 mg in children aged 6 to 11 with attention-deficit/hyperactivity disorder (ADHD) and insomnia. The trial was stopped early by the data safety monitoring board after a pre-specified analysis found statistically higher rates of neuropsychiatric adverse events in the eszopiclone arms compared with placebo. [3]

Reported events included hallucinations, agitation, and aggression. The FDA subsequently required labeling language warning prescribers of these risks in pediatric populations, even in off-label use contexts. A 2019 FDA Drug Safety Communication reinforced that complex sleep behaviors, including sleepwalking and sleep driving, are potential risks with all approved hypnotics. [4]

What "Off-Label Use" Means in This Context

Off-label prescribing is legal and sometimes clinically defensible, but it places the full burden of informed consent and monitoring on the prescribing clinician. When a child under 12 received eszopiclone off-label, whether for primary insomnia, autism spectrum disorder-related sleep disturbance, or ADHD-comorbid insomnia, their chart should document the rationale, the discussion of known risks, and the monitoring plan. That documentation becomes the starting point for an adult-care transition review.

The Regulatory and Safety Evidence Base

Understanding what the data actually say is essential before any transition decision is made.

FDA Label History and Dose Changes

The original 2004 FDA approval set the adult starting dose at 2 mg. [5] A 2014 safety update required dose reduction to 1 mg as the new standard starting point after studies showed that 2 mg produced blood concentrations the morning after ingestion that impaired driving performance, even when patients felt subjectively alert. The label specifies that women are disproportionately affected due to slower eszopiclone clearance, reaching area-under-the-curve (AUC) values approximately 45% higher than men at the same dose. [1]

No equivalent pediatric pharmacokinetic dataset exists in the published literature or the FDA database to guide weight-based dosing in children under 12, which is itself a reason the drug remains unapproved for this population.

Neuropsychiatric Signal in Younger Patients

The terminated trial described above was not the only source of concern. A review of FDA Adverse Event Reporting System (FAERS) data published in Pharmacotherapy identified pediatric case reports of eszopiclone-associated hallucinations across multiple age groups under 18. [6] The incidence in adults from key trials was roughly 1 to 3%, but the pediatric neuropsychiatric event rate in the terminated RCT exceeded that threshold at interim analysis.

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline on behavioral and pharmacological therapies for chronic insomnia in adults makes no recommendations for eszopiclone use below the age of 18, and its pediatric insomnia guidelines recommend behavioral interventions as the sole first-line approach for children. [7]

Abuse Potential and Scheduling

Eszopiclone is DEA Schedule IV. Dependence and withdrawal have been documented with therapeutic use in adults, and tolerance develops within two to four weeks of nightly dosing in some patients. [8] When a child who took eszopiclone for two or more years enters adult care, the transition clinician must assess for physiological dependence before any taper or substitution.

Building the Transition Plan: A Step-by-Step Framework

Transitioning a pediatric eszopiclone patient to adult sleep medicine care requires a structured process. The framework below integrates guidance from the American Academy of Pediatrics (AAP), AASM, and published transition-care models for chronic pediatric pharmacotherapy.

Step 1: Start Planning at Age 16 to 17, Not at 18

Adult clinics that receive patients with no prior transition planning face abrupt handoffs with incomplete records. The AAP policy statement on health care transitions recommends that formal planning begin no later than age 14, with active preparation between 16 and 18. [9] For a controlled substance like eszopiclone, a 12-to-18-month runway is appropriate.

During this window, the pediatric prescriber should:

• Review the original insomnia diagnosis and whether it is still accurate
• Document current dose, duration of use, and any dose escalations
• Provide a written medication summary including adverse events observed
• Assess for dependence using validated tools such as the Benzodiazepine Dependence Questionnaire (BDEPQ), which has been applied to Z-drug dependence in published research [8]
• Identify the receiving adult clinician and confirm they have received the full record

Step 2: Re-Evaluate the Insomnia Diagnosis in the Adult Framework

Insomnia disorder in adults is defined by the International Classification of Sleep Disorders, Third Edition (ICSD-3), as difficulty initiating or maintaining sleep at least three nights per week for at least three months, with associated daytime impairment, and not better explained by another sleep or medical disorder. [10]

Children often present with insomnia driven by behavioral factors, parental reinforcement, circadian misalignment, or neurodevelopmental comorbidities. As patients enter adolescence and early adulthood, the phenotype of their sleep disorder may shift substantially. A patient arriving at an adult clinic at age 18 on eszopiclone may now meet criteria for delayed sleep-wake phase disorder rather than primary insomnia, a diagnosis for which eszopiclone is not the appropriate treatment.

Polysomnography or actigraphy may be warranted at the transition visit to re-characterize the underlying sleep pathology before continuing the prescription.

Step 3: Introduce CBT-I Before or During the Transition

The AASM 2021 update to its clinical practice guideline recommends CBT-I as the first-line treatment for chronic insomnia in adults, with a strong recommendation rating. [7] A meta-analysis of 87 trials (N = 6,920 participants) published in JAMA Psychiatry found that CBT-I reduced sleep-onset latency by a mean of 19.0 minutes and wake after sleep onset by 26.0 minutes compared to control, with effects sustained at 12-month follow-up. [11]

For a young adult transitioning off or continuing eszopiclone, enrolling in a structured CBT-I program gives the adult prescriber a realistic option for dose reduction or discontinuation within three to six months, rather than indefinite pharmacotherapy.

Step 4: Plan the Eszopiclone Taper if Indicated

If the adult clinician decides to discontinue eszopiclone, abrupt cessation after prolonged use risks rebound insomnia and potential withdrawal. A slow taper of no more than 10 to 25% dose reduction per two to four weeks is consistent with Z-drug deprescribing protocols described in published guidelines. [12]

Concretely: a patient on eszopiclone 2 mg nightly might follow this sequence.

1. Weeks 1 to 2: Continue 2 mg, add CBT-I sessions
2. Weeks 3 to 6: Reduce to 1.5 mg (splitting doses is off-label; use 1 mg and 2 mg on alternating nights)
3. Weeks 7 to 12: Reduce to 1 mg nightly
4. Weeks 13 to 18: Reduce to 1 mg every other night
5. Weeks 19 to 20: Discontinue, continue CBT-I maintenance

Melatonin 0.5 to 1 mg taken 30 minutes before the target sleep time may support circadian regulation during the taper without adding controlled-substance risk, though evidence for its use specifically during Z-drug tapers is limited to small open-label series. [13]

Step 5: Document the Controlled Substance Transfer

Because eszopiclone is Schedule IV, prescribers in adult care settings must comply with their state's Prescription Monitoring Program (PMP) requirements. At the transition visit, the adult prescriber should:

• Query the state PMP to confirm the patient's current prescription history
• Confirm no concurrent benzodiazepine prescriptions (co-prescription substantially raises sedation and fall risk)
• Establish a new treatment agreement if the practice uses them for Schedule IV medications
• Set a 30-day follow-up visit, not a 90-day refill with no contact

Alternatives to Eszopiclone in the Pediatric-to-Adult Transition Period

Not every transition patient will require continued pharmacotherapy. For those who do, safer options exist.

Melatonin

Low-dose melatonin (0.5 to 3 mg) has the strongest evidence base for pediatric sleep-onset delay and is used across both pediatric and adult sleep clinics. A Cochrane review of melatonin for chronic insomnia identified benefit for sleep latency with a favorable safety profile. [13] It is not Schedule IV, not associated with dependence, and appropriate for bridging the transition while CBT-I takes effect.

Doxylamine or Diphenhydramine

These over-the-counter antihistamines are not recommended for ongoing use in any age group due to rapid tolerance development (typically within three to five nights) and residual anticholinergic effects. They are not an appropriate long-term substitute for eszopiclone in the transition context. [7]

Cognitive Behavioral Therapy for Insomnia (CBT-I)

CBT-I is non-pharmacological and has no dependence risk. Digital CBT-I programs (dCBT-I), including platforms studied in RCTs such as Sleepio (evaluated in a 2017 JAMA Psychiatry trial of N = 1,711), achieve effect sizes comparable to in-person therapy and are accessible to young adults without specialty referrals. [11]

Low-Dose Doxepin

The FDA approved doxepin 3 mg and 6 mg (brand: Silenor) for adult sleep maintenance insomnia in 2010. [14] Unlike eszopiclone, it lacks abuse potential and is not scheduled. For a young adult whose primary complaint is middle-of-the-night awakening rather than sleep-onset difficulty, low-dose doxepin is a reasonable alternative to consider at the transition.

Lemborexant or Suvorexant

Orexin receptor antagonists (suvorexant, FDA-approved 2014; lemborexant, FDA-approved 2019) block wake-promoting orexin signaling rather than enhancing GABA-A activity. [15] Neither is approved for patients under 18, but for a transitioning patient aged 18 or older they represent a mechanistically distinct option with a lower neuropsychiatric adverse event profile than Z-drugs. The 2020 SUNRISE-2 trial (N = 900) showed lemborexant 5 mg significantly improved sleep efficiency versus placebo over six months (P<0.001). [15]

Special Populations Within the Under-12 Transition Cohort

Autism Spectrum Disorder (ASD) and Sleep

Children with ASD have insomnia prevalence rates of 50 to 80%, compared to 20 to 30% in neurotypical children. [16] Some of these children received eszopiclone off-label. Transitioning them requires ASD-competent adult providers, because melatonin dysregulation is a distinct mechanism in this population and behavioral strategies require modification for communication and sensory profiles.

Pediatric Annals published a review noting that melatonin supplementation in ASD reduces sleep-onset latency by a mean of 47 minutes in randomized trials. [16] That signal supports melatonin as a preferred pharmacological bridge at transition in this subgroup.

ADHD and Comorbid Insomnia

ADHD stimulant medications can worsen sleep-onset insomnia, and some of the children who received eszopiclone off-label had ADHD as the primary diagnosis with insomnia as a secondary symptom. Optimizing ADHD pharmacotherapy, such as switching from an immediate-release amphetamine dosed in the afternoon to a lower dose with an earlier cutoff, may resolve the insomnia entirely and eliminate the need for any hypnotic at transition. [17]

Clinician Communication Across the Transition

Adult providers receiving young patients from pediatric practices frequently report receiving inadequate medication summaries. A 2018 survey of adult primary care physicians published in Pediatrics found that 47% reported never receiving a formal transition document for patients transferring from pediatric subspecialists. [9]

For controlled substances, this gap creates real legal and clinical risk. The pediatric prescriber should provide:

• A signed transition summary including diagnosis, dose, start date, and rationale for off-label use
• Any adverse event history during treatment
• Laboratory or polysomnographic data relevant to the sleep diagnosis
• A clear statement of whether taper has begun and if so, the current taper schedule

The adult prescriber should send a receipt confirmation and schedule the first visit within 30 days of transfer, not at the next available opening three months out.

As the AASM 2017 guideline states directly: "Clinicians should use psychological and behavioral interventions as the initial treatment for chronic insomnia disorder... Pharmacological interventions, when used, should be initiated at the lowest effective dose for the shortest necessary duration." [7]

Summary of Key Clinical Points

The following table captures the core decision points a clinician encounters when receiving a pediatric eszopiclone patient into adult care.

| Clinical Question | Answer | |---|---| | Is eszopiclone FDA-approved in this patient? | No, not until age 18, and no pediatric indication exists at any age | | Is physiological dependence possible? | Yes, particularly with more than 4 weeks of nightly use | | What should trigger an immediate taper? | Neuropsychiatric symptoms, dose escalation without prescriber approval, or concurrent benzodiazepine use | | What is first-line treatment at transition? | CBT-I; pharmacotherapy reserved for cases where behavioral therapy has failed or is inaccessible | | What is the safest pharmacological bridge? | Melatonin 0.5 to 3 mg, no schedule, no dependence risk | | When must PMP be queried? | At first adult-care prescription and at each renewal in states requiring real-time PMP access |

The FDA prescribing information for eszopiclone specifies that the 1 mg starting dose applies to all adults, and dose escalation to 3 mg is reserved for cases where 2 mg has been inadequate after clinical assessment, not for routine titration. [1] A transitioning patient already on 2 mg from a pediatric prescriber should be reassessed against that adult framework before the dose is continued without question.